Chinese expert consensus on the management of chimeric antigen receptor T cell therapy-associated coagulopathy.
作者信息
Mei Heng, Chen Fangping, Han Yue, Hou Ming, Huang He, Huang Xiaojun, Li Yuhua, Liang Aibin, Liu Qifa, Niu Ting, Peng Jun, Qian Wenbin, Song Yongping, Wang Jianxiang, Wang Ying, Wu Depei, Xu Kailin, Yang Linhua, Yang Renchi, Zhang Lei, Zhang Liansheng, Zhang Xi, Zhang Xiaohui, Zhao Weili, Han Weidong, Hu Yu
机构信息
Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
Department of Hematology, Xiangya Third Hospital, Central South University, Changsha, Hunan 410013, China.
出版信息
Chin Med J (Engl). 2022 Jul 20;135(14):1639-1641. doi: 10.1097/CM9.0000000000002288.
Abstract
摘要
相似文献
1
Chinese expert consensus on the management of chimeric antigen receptor T cell therapy-associated coagulopathy.嵌合抗原受体T细胞疗法相关凝血病管理的中国专家共识
Chin Med J (Engl). 2022 Jul 20;135(14):1639-1641. doi: 10.1097/CM9.0000000000002288.
2
[Consensus of Chinese experts on the clinical management of chimeric antigen receptor T-cell-associated neurotoxicity (2022)].《中国专家关于嵌合抗原受体T细胞相关神经毒性临床管理的共识（2022年）》
Zhonghua Xue Ye Xue Za Zhi. 2022 Feb 14;43(2):96-101. doi: 10.3760/cma.j.issn.0253-2727.2022.02.002.
3
Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy.嵌合抗原受体T细胞疗法后的继发性癌症
N Engl J Med. 2024 Feb 15;390(7):584-586. doi: 10.1056/NEJMp2400209. Epub 2024 Jan 24.
4
Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care center.门诊嵌合抗原受体（CAR）T细胞疗法的安全性与可行性：来自三级医疗中心的经验
Bone Marrow Transplant. 2022 Jun;57(6):1025-1027. doi: 10.1038/s41409-022-01664-z. Epub 2022 Apr 11.
5
Organ toxicities associated with chimeric antigen receptor T-cell therapy.嵌合抗原受体T细胞疗法相关的器官毒性。
Leuk Lymphoma. 2023 Feb;64(2):491-494. doi: 10.1080/10428194.2022.2148213. Epub 2022 Nov 23.
6
The use of chimeric antigen T-cell therapy in chronic lymphocytic leukemia.嵌合抗原T细胞疗法在慢性淋巴细胞白血病中的应用。
Clin Adv Hematol Oncol. 2022 Jun;20(6):366-368.
7
Coagulopathy in CAR-T: Critical concern or mere blip?嵌合抗原受体 T 细胞治疗后凝血功能障碍：关键关注点还是无关紧要？
Br J Haematol. 2024 Aug;205(2):409-410. doi: 10.1111/bjh.19619. Epub 2024 Jun 28.
8
Efficacy and safety of CAR-T cell therapy in minorities.嵌合抗原受体T细胞（CAR-T）疗法在少数群体中的疗效与安全性。
Bone Marrow Transplant. 2022 Jul;57(7):1187-1190. doi: 10.1038/s41409-022-01670-1. Epub 2022 Apr 28.
9
The evolving landscape of chimeric antigen receptor T-cell therapy associated cardiotoxicity.嵌合抗原受体T细胞疗法相关心脏毒性的不断演变态势。
Am J Emerg Med. 2022 Jul;57:220-221. doi: 10.1016/j.ajem.2022.02.021. Epub 2022 Feb 20.
10
Immune Effector Cell-Associated Neurotoxicity Syndrome Related to Chimeric Antigen Receptor T-Cell Therapy.与嵌合抗原受体T细胞疗法相关的免疫效应细胞相关神经毒性综合征
Neurology. 2024 Apr 23;102(8):e209266. doi: 10.1212/WNL.0000000000209266. Epub 2024 Mar 20.
引用本文的文献
1
Immunotherapy-associated hemostatic abnormalities: bleeding and thrombotic complications.免疫治疗相关的止血异常：出血和血栓形成并发症。
Ann Hematol. 2025 Jul;104(7):3537-3551. doi: 10.1007/s00277-025-06482-z. Epub 2025 Jul 1.
2
New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies.嵌合抗原受体T细胞血液学毒性的新见解：表现、机制及有效管理策略
Exp Hematol Oncol. 2024 Nov 9;13(1):110. doi: 10.1186/s40164-024-00573-9.
3
[Long-term follow-up of humanized and murine CD19 CAR-T-cell therapy for B-cell acute lymphoblastic leukemia].人源化和鼠源化CD19嵌合抗原受体T细胞疗法治疗B细胞急性淋巴细胞白血病的长期随访
Zhonghua Xue Ye Xue Za Zhi. 2023 Oct 14;44(10):793-799. doi: 10.3760/cma.j.issn.0253-2727.2023.10.001.
4
IL-10 plus the EASIX score predict bleeding events after anti-CD19 CAR T-cell therapy.IL-10 联合 EASIX 评分可预测抗 CD19 CAR T 细胞治疗后的出血事件。
Ann Hematol. 2023 Dec;102(12):3575-3585. doi: 10.1007/s00277-023-05477-y. Epub 2023 Oct 9.
5
Bridging chimeric antigen receptor T-cell before transplantation improves prognosis of relapsed/refractory B-cell acute lymphoblastic leukemia.移植前桥接嵌合抗原受体T细胞可改善复发/难治性B细胞急性淋巴细胞白血病的预后。
Chin Med J (Engl). 2023 Aug 20;136(16):2011-2013. doi: 10.1097/CM9.0000000000002764. Epub 2023 Jul 18.
Zotero 插件